There are 4 FDA-approved therapies now available to the NMOSD community. The Sumaira Foundation is pleased to share the first-of-its-kind, NMOSD Therapies Chart.
Our goal in laying out these new and available therapies side-by-side is to empower the patient community to discuss their treatment options with their doctors to make informed decisions about their best paths forward. At TSF, we’re strong advocates for shared decision-making between patients and their physicians, especially when it comes to deciding what long-term treatment(s) to opt for.
This chart has been created by TSF. Our Foundation works with therapy makers equally with an unbiased and objective lens.
Special thanks to Dr. Michael Levy (subject-matter expert), Andrea Sydney (volunteer project manager), and 3Dcubed (animator) for their support in bringing this chart to fruition.
Legend:
– Animated video for explanation
– Definition in text and audio format
 Soliris® (eculizumab) |  Uplizna® (inebilizumab-cdon) |  Enspryng® (satralizumab) |  ULTOMIRIS® (ravulizumab-cwvz) | |
| Pharmacology | Complement Inhibitor | B Cell Depletion | Interleuken-6 (IL-6) Inhibitor | Complement inhibitor |
| Drug Delivery Method | Infusion (35 minutes) | Infusion (90 minutes) | Subcutaneous injection that is self-administered | IV Infusion (30 minutes to less than 1 hour, depending on body weight) |
| Frequency | Every 2 weeks,
after 5 initial doses once per week | Every 6 months,
after 2 initial doses 2 weeks apart | Every 4 weeks,
after 1 dose every 2 weeks for the first 4 weeks | Every 8 weeks, 2 weeks after initial loading dose |
| Dosage | 1200 mg | 300 mg | 120 mg | 3000 – 3600 mg, depending on body weight |
| Antibody Criteria | AQP4+ NMOSD (MOG untested) | AQP4+ NMOSD (MOG untested) | AQP4+ NMOSD (MOG untested) | AQP4+ NMOSD (MOG untested) |
| Common Side Effects | Common side effects vary,
see important safety information Important Safety Information and Indication for SOLIRIS (eculizumab) | Common side effects vary,
see important safety information Important Safety Information and Indication for UPLIZNA (inebiluzumab) | Common side effects vary,
see important safety information Important Safety Information and Indication for ENSPRYNG (satralizumab) | Common side effects vary,
see important safety information Important Safety Information and Indication for ULTOMIRIS (ravulizumab) |
| Potential Serious Side Effects | Meningococcal infections and infusion reactions | Infusion reactions, infections and low blood cell counts | Infections, increased liver enzymes and low neutrophil counts | Meningococcal infections and infusion reactions |
| Manufacturer |  |  |  | |
| Assistance Programs | Alexion OneSourceTM | Amgen By Your Side | ENSPRYNG Financial Support Tool | Alexion OneSourceTM |
| Prescribing Information | Soliris ® Prescribing Information | Uplizna® Prescribing Information | Enspryng™ Prescribing Information | Ultomiris® Prescribing Information |
